The company continues to work on the production of products such as the double vaccine for covid and flu, and to treat other respiratory conditions.
File photo of the American pharmaceutical company Moderna.
Foto: CJ GUNTHER
–
The American pharmaceutical company Moderna earned between January and March 3,657 million dollars, almost three times more than the 1,221 million achieved in the same quarter of 2021, thanks to the sales of its vaccine against covid-19, which shot up to 5,925 million. of dollars.
The company also tripled its revenue in the first quarter, which reached 6,066 million dollars, compared to 1,937 achieved in the same period last year.
Likewise, its earnings per share between January and March also soared to $8.58, compared to the first quarter of 2021, when they stood at $2.84.
The company also reiterated that its sales forecast for the covid-19 vaccine for the whole year is 21,000 million dollars.
“Moderna’s team had a strong first quarter performance and I am grateful for the progress our team continues to make as we advance our mRNA drug portfolio,” said CEO Stéphane Bancel.
Bancel highlighted that the company continues to work on the production of several products such as the double vaccine for covid and flu, and to treat other respiratory conditions.
Last week, Moderna asked US and European Union health authorities the emergency authorization of your vaccine against covid-19 for children between six months and six years.
This Wednesday, after disclosing its accounts, the company’s shares soared up to 6.11% in electronic operations prior to the opening of the New York Stock Exchange.
Also read: Moderna says a new version of its vaccine works better against variants
–
© 360 TELECOM CORPORATION
–
